Non-Invasive Prenatal Testing (NIPT) is a method to determine risks associated with certain genetic abnormalities in fetuses. Noninvasive prenatal testing (NIPT), also referred to as Non-Invasive Prenatal Screening (NIPS), involves analysis of small fragments of DNA that are circulating in a pregnant woman's blood. These fragments of DNA, called cell-free DNA (cfDNA), are obtained from the placenta and provide an opportunities for early detection of certain genetic abnormalities. The test is preferred owing to its noninvasive nature, which involves collecting a blood sample only from pregnant women without posing any risks to the fetus. NIPT is primarily performed for the identification of chromosomal disorders such as Down syndrome (also called trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome. In addition, it can also screen additional chromosomal disorders, which are caused due to missing (deleted) or copied (duplicated) sections of a chromosome.
Market Industry Reports (MIR) has published a new report titled "Non-Invasive Prenatal Testing (NIPT) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2030." According to the report, the global non-invasive prenatal testing market accounted for over US$ 1.5 Bn in 2019. It is anticipated to grow at a CAGR of approximately 16.2% from 2019 to 2030.Major Key Players of the Non-Invasive Prenatal Testing (NIPT) Market are:
Illumina, Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd, QIAGEN, BGI, Agilent Technologies, Inc., Natera, Inc., YOURGENE HEALTH, CENTOGENE N.V., and PerkinElmer Inc., among others.
No comments:
Post a Comment